Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PlexBio CoROCO:6572 -0.13%68 Debt-to-EBITDA is -0.21 as of Jun. 2026. GuruFocus rates ROCO:6572 with a GF Score™ of 68/100 and a GF Value™ of NT$10.49 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 475 Medical Devices & Instruments companies, PlexBio Co ranks worse than 210526.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PlexBio Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6572'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.41 Med: -0.13 Max: 0
Current: -0.23
ROCO:6572's Debt-to-EBITDA is ranked worse than 100% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs ROCO:6572: -0.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PlexBio Co Debt-to-EBITDA Related Terms
PlexBio Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PlexBio Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6572 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, PlexBio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PlexBio Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PlexBio Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PlexBio Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
PlexBio Co (ROCO:6572) has a Debt-to-EBITDA of -0.21 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PlexBio Co. According to the industry distribution chart, PlexBio Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is PlexBio Co's Debt-to-EBITDA too high?
PlexBio Co's current Debt-to-EBITDA is -0.21. Based on the distribution chart, PlexBio Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PlexBio Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PlexBio Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PlexBio Co ranks #999999 out of 475 companies for Debt-to-EBITDA. This places PlexBio Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PlexBio Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PlexBio Co's current Debt-to-EBITDA is -0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PlexBio Co stock overvalued right now?
Based on GuruFocus' analysis, PlexBio Co (ROCO:6572) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$10.49, compared to a current price of NT$7.72 — trading 26.4% below its estimated fair value. The current Debt-to-EBITDA is -0.21. PlexBio Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PlexBio Co (ROCO:6572), the current Debt-to-EBITDA is -0.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PlexBio Co (ROCO:6572) Overvalued in 2026?
Based on GuruFocus' analysis, PlexBio Co stock appears to be undervalued.
The current stock price of NT$7.72 is trading 26.4% below its estimated GF Value™ of NT$10.49.
GuruFocus considers PlexBio Co to be Modestly Undervalued.
Key valuation signals for ROCO:6572:
Debt-to-EBITDA: -0.21
GF Value™: NT$10.49 vs. price of NT$7.72 (26.4% below fair value)
No single metric tells the full story. See the ROCO:6572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PlexBio Co Ltd is a Taiwan based company involved in designing, developing and manufacturing IVD products and instrumentations. Its products are used in companion diagnostic panel, early cancer detection screening, prenatal diagnostics and for food and safety testing.
68GF Score
Get the complete analysis for ROCO:6572
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6572 has been successfully added to your 
